Anixa Biosciences (ANIX) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free ANIX Stock Alerts $3.01 +0.04 (+1.35%) (As of 02:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 2:10 AM | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Trading Down 1%May 8, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 8, 2024 | msn.comAnixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccinesMay 8, 2024 | markets.businessinsider.comAnixa Inks Joint Development Agreement With Cleveland Clinic To Develop Novel Cancer VaccinesMay 8, 2024 | prnewswire.comAnixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 6, 2024 | prnewswire.comAnixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay JunejaApril 30, 2024 | prnewswire.comAnixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024April 18, 2024 | finance.yahoo.comAnixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory BoardApril 11, 2024 | insidertrades.comLewis H. Titterton, Jr. Acquires 15,009 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockApril 10, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Buys 15,009 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 15,009 shares of the firm's stock in a transaction dated Tuesday, April 9th. The stock was purchased at an average cost of $3.28 per share, with a total value of $49,229.52. Following the transaction, the director now owns 838,037 shares in the company, valued at $2,748,761.36. The purchase was disclosed in a legal filing with the SEC, which is available at this link.March 22, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) to Post Q1 2025 Earnings of ($0.11) Per Share, HC Wainwright ForecastsAnixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Anixa Biosciences in a report issued on Thursday, March 21st. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.1March 21, 2024 | marketbeat.comAnixa Biosciences' (ANIX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Anixa Biosciences in a research report on Thursday.March 18, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Up 8.2% in FebruaryAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 618,200 shares, a growth of 8.2% from the February 14th total of 571,500 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average trading volume of 211,200 shares, the days-to-cover ratio is currently 2.9 days.March 16, 2024 | finance.yahoo.comANIX Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comANIX Apr 2024 2.500 putMarch 16, 2024 | insidertrades.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $36,300.00 in StockMarch 15, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $36,300.00 in StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies purchased 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The stock was bought at an average price of $3.63 per share, with a total value of $36,300.00. Following the transaction, the director now directly owns 110,000 shares in the company, valued at $399,300. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.March 14, 2024 | prnewswire.comAnixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested PartiesMarch 12, 2024 | benzinga.comRecap: Anixa Biosciences Q1 EarningsMarch 11, 2024 | prnewswire.comAnixa Biosciences Announces Presentation at 24th Annual World Vaccine CongressFebruary 22, 2024 | benzinga.comAnixa Biosciences Stock (NASDAQ:ANIX) Insider TradesFebruary 21, 2024 | investing.comAnixa Biosciences Inc (ANIX)February 17, 2024 | finance.yahoo.comWe Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business GrowthFebruary 17, 2024 | finance.yahoo.comANIX Feb 2024 5.000 callFebruary 15, 2024 | marketbeat.comAnixa Biosciences, Inc. Expected to Post FY2025 Earnings of ($0.40) Per Share (NASDAQ:ANIX)Anixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Analysts at HC Wainwright issued their FY2025 earnings estimates for Anixa Biosciences in a report issued on Tuesday, February 13th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.40) per share for the year. HC WainwrightFebruary 13, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)February 13, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Anixa Biosciences in a report on Tuesday.February 12, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical TrialFebruary 12, 2024 | finance.yahoo.comAnixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical TrialFebruary 6, 2024 | finance.yahoo.com3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023January 30, 2024 | ca.finance.yahoo.comDogs Can Suffer from Depression — Here Are Signs to Look Out for and How to Diagnosis ThemJanuary 30, 2024 | msn.comHere’s Why You Get a Runny Nose When You’re EatingJanuary 30, 2024 | ca.news.yahoo.comVisible wants to track your illness, more than your fitnessJanuary 30, 2024 | ca.finance.yahoo.comRecalled cinnamon applesauce pouches were never tested for lead, FDA reportsJanuary 30, 2024 | ca.style.yahoo.comIf You Suffer From Intense PMS, This Condition Could Be The CauseJanuary 30, 2024 | ca.style.yahoo.comKing Charles smiles as he leaves hospital following prostate procedureJanuary 30, 2024 | msn.comKristen Dahlgren: Why I’m leaving NBC to launch a nonprofit to make breast cancer vaccines a realityJanuary 29, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Up 10.7% in JanuaryAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 670,900 shares, a growth of 10.7% from the December 31st total of 606,100 shares. Approximately 2.2% of the company's shares are short sold. Based on an average daily volume of 183,400 shares, the days-to-cover ratio is currently 3.7 days.January 29, 2024 | finance.yahoo.comAnixa Biosciences Announces Participation in 2024 NeauxCancer Oncology ConferenceJanuary 23, 2024 | msn.comAnixa ovarian cancer vaccine tech gets Japanese patentJanuary 23, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine TechnologyJanuary 23, 2024 | finance.yahoo.comAnixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine TechnologyJanuary 10, 2024 | finance.yahoo.comAnixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024January 2, 2024 | marketbeat.comMission Wealth Management LP Invests $1.64 Million in Anixa Biosciences, Inc. (NASDAQ:ANIX)Mission Wealth Management LP bought a new stake in shares of Anixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 501,168 shares of the company's stock, valuedJanuary 1, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Up 14.2% in DecemberAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 661,500 shares, an increase of 14.2% from the November 30th total of 579,200 shares. Currently, 2.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 141,900 shares, the short-interest ratio is currently 4.7 days.December 20, 2023 | benzinga.comAnixa Biosciences, A New Type Of Biotech Company: Could It Disrupt The Cancer Landscape?December 18, 2023 | msn.comBreast cancer vaccine could prevent most aggressive form of disease from reoccurringDecember 14, 2023 | msn.comBreast cancer vaccine present positive dataDecember 14, 2023 | finance.yahoo.comAnixa Biosciences to Present at Biotech Showcase 2024December 12, 2023 | msn.comHumanity May Conquer Breast Cancer Soon Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Revolutionizing the Green Energy Space and Building Shareholder Value Along the Way (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely! Learn how this American company is leading the lithium-ion revolution ANIX Media Mentions By Week ANIX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIX News Sentiment▼-0.110.57▲Average Medical News Sentiment ANIX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIX Articles This Week▼82▲ANIX Articles Average Week Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Milestone Pharmaceuticals News ProPhase Labs News Aclaris Therapeutics News Eton Pharmaceuticals News Clearside Biomedical News Oncolytics Biotech News Spero Therapeutics News Chimerix News Oramed Pharmaceuticals News Barinthus Biotherapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
